Who are Fendilin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sensipar, Upasita, Orkedia, L-Tryptophan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fendiline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Fendilin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fendilin (FENDILINE) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: fendiline. Area: Cardiovascular.

phase 2 fendiline Extracellular calcium-sensing receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Fendilin (FENDILINE). Fendiline works by binding to the extracellular calcium-sensing receptor, which helps regulate calcium levels in the body.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fendilin TARGET	FENDILINE		phase 2	fendiline	Extracellular calcium-sensing receptor
Sensipar	CINACALCET	Amgen	marketed	Calcium-sensing Receptor Agonist	Extracellular calcium-sensing receptor	2004-01-01
Upasita	UPACICALCET	SANWA KAGAKU KENKYUSHO Co., Ltd.	marketed		Extracellular calcium-sensing receptor
Orkedia	EVOCALCET	Kyowa Hakko Kirin Co., Ltd.	marketed		Extracellular calcium-sensing receptor
L-Tryptophan	TRYPTOPHAN		marketed	tryptophan	Myeloperoxidase, Extracellular calcium-sensing receptor, Probable G-protein coupled receptor 139

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (fendiline class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fendilin — Competitive Intelligence Brief. https://druglandscape.com/ci/fendiline. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing